Welcome to EndoCyclic Therapeutics
Developing the first non-hormonal therapeutic for endometriosis
Endometriosis has been considered the greatest overlooked epidemic in women’s health. At least 10% of girls and women worldwide have endometriosis, affecting all ethnicities alike. It is the leading cause of female infertility, chronic pelvic pain, and gynecologic surgeries.
Shockingly, to date, there is no cure for endometriosis. The current management protocols include hormone and pain therapies which still fail to reverse the disease or address the root cause. Patients must often resort to surgery, leaving the possibility for reoccurrence.
As the number one cause of disability in women in their reproductive years, endometriosis is currently affecting over 176 million women worldwide and their ability to work, parent, or simply enjoy life.
Why It Matters
Straight to the Cause
EndoCyclic Therapeutics is developing a treatment for endometriosis that addresses the root cause of the disease. We aim to give women afflicted by endometriosis the chance to finally enjoy remission from this painful disease.
Small Molecule Therapeutics
We are developing revolutionary small molecules that can invade endometriosis disease cells at the source. These molecules are “first-in-class” and bind to directly to non-hormonal targets.
Thorough Research Methodology
We have discovered a new biochemical pathway that triggers endometriosis. We are designing novel targeted therapeutics that disrupt disease initiation without the use of hormones.
Helping Women Live Pain-Free Lives
At EndoCyclic Therapeutics, our mission is to stop the suffering of millions of women - and their families - who are affected by endometriosis.
Our team includes the top talent from medicine, biology, chemistry, bioinformatics, and engineering who have come together to focus their energies on this serious women health issue. Our goal is to liberate millions of women from the pain and infertility caused by endometriosis.
Whether you are a patient, physician, advocate, academic, investor, or potential industry partner, we want to hear from you. Contact us to see how you can get involved.